Xilio Therapeutics, Inc.
XLO
$0.70
-$0.0002-0.03%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -23.82% | -3.99% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -23.82% | -3.99% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -23.82% | -3.99% | |||
| SG&A Expenses | 3.33% | 8.46% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -10.04% | 0.21% | |||
| Operating Income | 7.93% | -0.88% | |||
| Income Before Tax | 6.61% | -0.68% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 6.61% | -0.68% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 6.61% | -0.68% | |||
| EBIT | 7.93% | -0.88% | |||
| EBITDA | 8.10% | -1.36% | |||
| EPS Basic | 8.37% | 30.27% | |||
| Normalized Basic EPS | 8.66% | 29.91% | |||
| EPS Diluted | 8.37% | 30.27% | |||
| Normalized Diluted EPS | 8.66% | 29.91% | |||
| Average Basic Shares Outstanding | 1.91% | 44.40% | |||
| Average Diluted Shares Outstanding | 1.91% | 44.40% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
